Optimal P2Y12 Inhibitor in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis

JACC: Cardiovascular Interventions

Volumn 9, Issue 10, 2016, Pages 1036-1046

  Rafique, Asim M ^a,b   Nayyar, Piyush ^a   Wang, Tracy Y ^c   Mehran, Roxana ^d   Baber, Usman ^d   Berger, Peter B ^e   Tobis, Jonathan ^b   Currier, Jesse ^b,f   Dave, Ravi H ^b   Henry, Timothy D ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

^e Northwell Health ^*  (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

angioplasty; clopidogrel; P2Y12 inhibitors; percutaneous coronary intervention; prasugrel; ST segment elevation myocardial infarction; thienopyridines; ticagrelor

Indexed keywords

ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; HIRULOG; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICAGRELOR; ADENOSINE; ANTITHROMBIN; BIVALIRUDIN; HIRUDIN DERIVATIVE; P2RY12 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PURINERGIC P2Y12 RECEPTOR; RECOMBINANT PROTEIN; TICLOPIDINE;

ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BAYES THEOREM; BLEEDING; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ELUTING CARDIOVASCULAR STENT; DRUG MEGADOSE; DRUG SAFETY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL (TOPIC); CORONARY THROMBOSIS; DEVICES; DRUG EFFECTS; DRUG ELUTING STENT; EVIDENCE BASED MEDICINE; MARKOV CHAIN; METABOLISM; MONTE CARLO METHOD; MORTALITY; NETWORK META-ANALYSIS; ODDS RATIO; RISK FACTOR; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE; TREATMENT OUTCOME;

ADENOSINE; ANTITHROMBINS; BAYES THEOREM; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HIRUDINS; HUMANS; MARKOV CHAINS; MONTE CARLO METHOD; NETWORK META-ANALYSIS; ODDS RATIO; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RECOMBINANT PROTEINS; RISK FACTORS; ST ELEVATION MYOCARDIAL INFARCTION; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84968779740     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.02.013     Document Type: Article

References (29)

1. J.A. Spertus, R. Kettelkamp, C. Vance, and et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry Circulation 113 2006 2803 2809
2. F. Airoldi, A. Colombo, N. Morici, and et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment Circulation 116 2007 745 754
3. M.P. Bonaca, P.G. Steg, L.J. Feldman, and et al. Antithrombotics in acute coronary syndromes J Am Coll Cardiol 54 2009 969 984
4. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
5. P.G. Steg, S.K. James, D. Atar, and et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
6. G. Patti, G. Bárczi, D. Orlic, and et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI randomized study J Am Coll Cardiol 58 2011 1592 1599
7. D. Trenk, W. Hochholzer, M.F. Fromm, and et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
8. S.D. Wiviott, E. Braunwald, C.H. McCabe, et al. TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
9. L. Wallentin, R.C. Becker, A. Budaj, et al. PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
10. D.E. Cutlip, S. Windecker, R. Mehran, and et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
11. E.G. Bovill, M.L. Terrin, D.C. Stump, and et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction, Phase II Trial Ann Intern Med 115 1991 256 265
12. J.P. Jansen, B. Crawford, G. Bergman, and W. Stam Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons Value Health 11 2008 956 964
13. M. Vavuranakis, D.A. Vrachatis, T.G. Papaioannou, and et al. Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. Impact on intracoronary thrombus burden and myocardial perfusion Circ J 75 2011 2105 2112
14. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabloizers of the drug. March 12, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed May 21, 2015.
15. P.L. L'Allier, G. Ducrocq, N. Pranno, et al. PREPAIR Study Investigators Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study J Am Coll Cardiol 51 2008 1066 1072
16. M.J. Price, P.B. Berger, P.S. Teirstein, et al. GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
17. T. Lhermusier, M.J. Lipinski, U.S. Tantry, and et al. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 115 2015 716 723
18. P.A. Gurbel, K.P. Bliden, K. Butler, and et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
19. B. Hibbert, R. Maze, A. Pourdjabbar, and et al. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study PLoS One 9 2014 e92078
20. D. Alexopoulos, A. Galati, I. Xanthopoulou, and et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study J Am Coll Cardiol 60 2012 193 199
21. D.J. Angiolillo, J.F. Saucedo, R. Deraad, et al. SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP study J Am Coll Cardiol 56 2010 1017 1023
22. G. Parodi, R. Valenti, B. Bellandi, and et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID primary PCI study J Am Coll Cardiol 61 2013 1601 1606
23. D. Trenk, G.W. Stone, M. Gawaz, and et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI study J Am Coll Cardiol 59 2012 2159 2164
24. Marciniak T. FDA Advisory Committee for Ticagrelor. Ticagrelor for acute coronary syndromes, NDA 22-433, changes from original version to amended version. July 28, 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM220193.pdf. Accessed May 21, 2015.
25. D. Alexopoulos, I. Xanthopoulou, V. Gkizas, and et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
26. G. Parodi, B. Bellandi, R. Valenti, and et al. Comparison of double ticagrelor loading dose with standard prasugrel loading dose in ST-elevation myocardial infarction patients: the RAPID primary PCI 2 study Am Heart J 167 2014 909 914
27. J.J. Dinicolantonio, and G. Biondi-Zoccai Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports Int J Cardiol 168 2013 633 635
28. J.J. Dinicolantonio, and V.L. Serebruany Exploring the ticagrelor-statin interplay in the PLATO trial Cardiology 124 2013 105 107
29. V.L. Serebruany, V. Cherepanov, A. Tomek, and M.H. Kim Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30day mortality in patients with ST-elevated myocardial infarction Int J Cardiol 195 2015 104 110